Clinical Trials Browser

Lymphoma

NCT04301076 2026-03-18

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1 Suspended

30 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00006721 2026-03-16

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Phase 3 Completed

571 enrolled 12 charts

Lymphoid

Lymphoma, Lymphoma, Follicular

NCT03223610 2026-03-12

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Phase 1/2 Recruiting

155 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

41 enrolled

Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-03-03

EPCORE™FL-2

Phase 3 Recruiting

1,095 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT04739813 2026-02-24

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1 Recruiting

55 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05371054 2026-02-23

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Phase 1/2 Completed

8 enrolled 20 charts

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Phase 4 Not yet recruiting

80 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

NCT06356129 2026-02-12

GOLSEEK-1

Phase 3 Active not recruiting

850 enrolled

Lymphoid

Lymphoma

NCT03943901 2026-01-29

Split-Dose R-CHOP for Older Adults With DLBCL

Phase 2 Active not recruiting

27 enrolled 11 charts

Lymphoid

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT06425302 2026-01-08

GOLSEEK-2

Phase 2 Active not recruiting

90 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular

NCT06692452 2026-01-07

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2 Suspended

24 enrolled

Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT01695005 2025-12-26

A Study of LY3039478 in Participants With Advanced Cancer

Phase 1 Completed

247 enrolled 53 charts

Lymphoid

Lymphoma, Neoplasm Metastasis, Neoplasms

Clinical Trials

BNHL-2015

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

EPCORE™FL-2

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

GOLSEEK-1

Split-Dose R-CHOP for Older Adults With DLBCL

GOLSEEK-2

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

A Study of LY3039478 in Participants With Advanced Cancer